Back

One-year outcomes with mavacamten in a real-world nationwide hypertrophic cardiomyopathy cohort: safety and efficacy

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibition in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Giacomo Bonacchi

Careggi University Hospital (AOUC), Florence (Italy)

5 More presentations in this session

Presentation thumbnail
Atrial fibrillation during mavacamten treatment in obstructive hypertrophic cardiomyopathy in the real-world: data from the multicenter MARVEL.HU registry on 133 patients
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Real world safety and efficacy of mavacamten for hypertrophic obstructive cardiomyopathy: the SWISS-MAVA cohort
Doctor D. Jensen (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Mavacamten to treat patients with obstructive HCM in Portugal: an interim analysis of the MAVA-PT cohort
Doctor D. Da Silva Correia (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Real-world experience with mavacamten therapy in patients with obstructive hypertrophic cardiomyopathy
Doctor S. Hoss (Petah Tikva, IL)
Abstract Slides Video
Presentation thumbnail
Impact of mavacamten on left atrial remodeling in obstructive hypertrophic cardiomyopathy: data from 3 portuguese centers
Doctor I. Miranda (Amadora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac myosin inhibition in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of functional status and quality-of-life improvement with mavacamten in obstructive hypertrophic cardiomyopathy: one-year results from a real-world nationwide cohort
31 August 2026
thumbnail
Congress Presentation
ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy
28 August 2026
thumbnail
Congress Presentation
Correlation of electrocardiographic reverse remodelling with treatment response to mavacamten in hypertrophic obstructive cardiomyopathy
31 August 2026
thumbnail
Congress Presentation
Mavacamten real-world experience: insights from the Dutch HCM Network.
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources